KEYNOTE-001: Five year data from the phase Ib trial studying pembrolizumab as tr...
Dr Edward B. Garon - UCLA, Los Angeles, USA
1 Jun 2019
Comment: The success of immunotherapy means we have to change our mindset as we ...
Dr David Graham and Dr Edward B. Garon
1 Jun 2019
Pembrolizumab is safe and effective and substantially increases overall survival...
Dr Edward B. Garon - UCLA, Los Angeles, USA
1 Jun 2019
Cardiac events following radical radiotherapy for lung cancer
Dr Fei Sun - Leeds Cancer Centre, Leeds, UK
10 May 2019
ALK-positive NSCLC: Treatments and latest developments
Prof Tony Mok - Chinese University of Hong Kong, Hong Kong
29 Apr 2019
ALK-positive NSCLC: Current landscape
Dr Antonio Passaro and Prof Rafal Dziadziuszko
29 Apr 2019
Latest data from KEYNOTE 42: Pembrolizumab vs chemotherapy in treatment-naive pa...
Prof Tony Mok - Chinese University of Hong Kong, Hong Kong
18 Apr 2019
Entrectinib in NTRK fusion-positive non-small cell lung cancer
Dr Luis Paz-Ares - Hospital Universitario Doce de Octubre, Madrid, Spain
18 Apr 2019
Using CT imaging to find radiomic signatures in surgically resected NSCLC
Giulia Mazzaschi - University Hospital Parma, Parma, Italy
18 Apr 2019
The role of afatinib in patients with EGFR NSCLC
Dr Antonio Passaro - European Institute of Oncology, Milan, Italy
18 Apr 2019
Efficacy and immune correlates of the SRA737 plus LDG regimen in combination wit...
Dr Triparna Sen - MD Anderson Cancer Center, Houston, Texas
15 Apr 2019
TATTON: Osimertinib plus savolitinib for patients with EGFR-mutant, MET-amplifie...
Prof Lecia Sequist - Massachusetts General Hospital, Boston, USA
15 Apr 2019
